We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MYGN Stock Might Rise on Collaboration With CancerCARE
Read MoreHide Full Article
Myriad Genetics, Inc. (MYGN - Free Report) recently announced an agreement to enhance education and access to hereditary cancer testing for CancerCARE for Life members.
Under the agreement, more than 1 million individuals within CancerCARE’s network will be able to assess their eligibility for the MyRisk test by taking the MyGeneHistory quiz. If they meet the criteria, they will be directed to a clinician who can order the MyRisk with RiskScore Hereditary Cancer Test on their behalf.
The latest collaboration is aimed at bolstering the company’s Hereditary Cancer testing business.
MYGN Stock’s Likely Trend Following the News
Myriad Genetic’s shares lost 1.5% last Thursday.
The company has been gaining synergies from its MyRisk Hereditary Cancer Test. In December 2024, the American Journal of Human Genetics named the MyRisk Hereditary Cancer Test with RiskScore study as one of the top 10 significant advances in genomic medicine.
Moreover, MyRisk is expected to continue its strong growth from expanded guidelines and acceleration of EMR integrations. Accordingly, we expect the latest collaboration to boost the market sentiment toward MYGN stock.
Myriad Genetics has a market capitalization of $1.13 billion. It has a long term EPS growth rate of 44% compared with the industry’s 20%. MYGN delivered a trailing four-quarter average earnings surprise of 247.73%.
About MYGN’s MyRisk Hereditary Cancer Test With RiskScore
MyRisk with RiskScore is the first and industry-leading hereditary cancer test and polygenic risk prediction test for all ancestries. It evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment.
About CancerCARE
CancerCARE and CancerCARE for Life comprise one of the nation’s largest prevention, early detection and cancer management programs. CancerCARE for Life’s unique approach blends targeted education and awareness with personalized oncology-trained nurses and physicians to deliver an exceptional member experience. CancerCARE has expertise in clinical trials, Center of Excellence access, pre-guideline care, NCCN Guideline care, and gene and cellular therapy, which helps ensure the best outcome for members.
More on the News
Myriad Genetic’s Breast Cancer Risk Assessment Program features the MyRisk with RiskScore Hereditary Cancer Test. It also includes MyGeneHistory, an online screening tool that helps assess if a patient meets medical guidelines for hereditary cancer testing. The program also includes patient education about genetic testing and a guide on how to collect family history of certain cancers.
Image Source: Zacks Investment Research
Industry Prospects Favoring MYGN
Per an Allied Market Research report, the global hereditary cancer testing market was valued at $3.5 billion in 2021 and is expected to grow at a compound annual rate of 11.6% through 2031. The increasing geriatric population, a surge in the incidence of cancer worldwide and an increase in government expenditures on healthcare are some of the main factors fueling the market’s growth.
Another Development by Myriad Genetics
In January, Myriad Genetics entered into an agreement with Hannah Storm, a nationally renowned sports broadcaster who recently revealed her battle with breast cancer. Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program, which features the MyRisk with RiskScore Hereditary Cancer test.
MYGN Stock Price Performance
In the past year, MYGN’s shares have lost 46% compared with the industry’s decline of 11.7%.
MYGN’s Zacks Rank and Key Picks
Myriad Genetics currently carries a Zacks Rank #4 (Sell).
Omnicell's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%. OMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year.
ResMed, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 21.1% for 2025. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year.
Veracyte, carrying a Zacks Rank #3 (Hold) at present, has an estimated earnings growth rate of 65.8% for 2025. VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MYGN Stock Might Rise on Collaboration With CancerCARE
Myriad Genetics, Inc. (MYGN - Free Report) recently announced an agreement to enhance education and access to hereditary cancer testing for CancerCARE for Life members.
Under the agreement, more than 1 million individuals within CancerCARE’s network will be able to assess their eligibility for the MyRisk test by taking the MyGeneHistory quiz. If they meet the criteria, they will be directed to a clinician who can order the MyRisk with RiskScore Hereditary Cancer Test on their behalf.
The latest collaboration is aimed at bolstering the company’s Hereditary Cancer testing business.
MYGN Stock’s Likely Trend Following the News
Myriad Genetic’s shares lost 1.5% last Thursday.
The company has been gaining synergies from its MyRisk Hereditary Cancer Test. In December 2024, the American Journal of Human Genetics named the MyRisk Hereditary Cancer Test with RiskScore study as one of the top 10 significant advances in genomic medicine.
Moreover, MyRisk is expected to continue its strong growth from expanded guidelines and acceleration of EMR integrations. Accordingly, we expect the latest collaboration to boost the market sentiment toward MYGN stock.
Myriad Genetics has a market capitalization of $1.13 billion. It has a long term EPS growth rate of 44% compared with the industry’s 20%. MYGN delivered a trailing four-quarter average earnings surprise of 247.73%.
About MYGN’s MyRisk Hereditary Cancer Test With RiskScore
MyRisk with RiskScore is the first and industry-leading hereditary cancer test and polygenic risk prediction test for all ancestries. It evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment.
About CancerCARE
CancerCARE and CancerCARE for Life comprise one of the nation’s largest prevention, early detection and cancer management programs. CancerCARE for Life’s unique approach blends targeted education and awareness with personalized oncology-trained nurses and physicians to deliver an exceptional member experience. CancerCARE has expertise in clinical trials, Center of Excellence access, pre-guideline care, NCCN Guideline care, and gene and cellular therapy, which helps ensure the best outcome for members.
More on the News
Myriad Genetic’s Breast Cancer Risk Assessment Program features the MyRisk with RiskScore Hereditary Cancer Test. It also includes MyGeneHistory, an online screening tool that helps assess if a patient meets medical guidelines for hereditary cancer testing. The program also includes patient education about genetic testing and a guide on how to collect family history of certain cancers.
Image Source: Zacks Investment Research
Industry Prospects Favoring MYGN
Per an Allied Market Research report, the global hereditary cancer testing market was valued at $3.5 billion in 2021 and is expected to grow at a compound annual rate of 11.6% through 2031. The increasing geriatric population, a surge in the incidence of cancer worldwide and an increase in government expenditures on healthcare are some of the main factors fueling the market’s growth.
Another Development by Myriad Genetics
In January, Myriad Genetics entered into an agreement with Hannah Storm, a nationally renowned sports broadcaster who recently revealed her battle with breast cancer. Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program, which features the MyRisk with RiskScore Hereditary Cancer test.
MYGN Stock Price Performance
In the past year, MYGN’s shares have lost 46% compared with the industry’s decline of 11.7%.
MYGN’s Zacks Rank and Key Picks
Myriad Genetics currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Omnicell (OMCL - Free Report) , ResMed (RMD - Free Report) and Veracyte (VCYT - Free Report) .
Omnicell, carrying a Zacks Rank #2 (Buy) at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. You can see the complete list of today’s Zacks #1 Rank stocks here.
Omnicell's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%. OMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year.
ResMed, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 21.1% for 2025. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year.
Veracyte, carrying a Zacks Rank #3 (Hold) at present, has an estimated earnings growth rate of 65.8% for 2025. VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.